Venita Chandra, MD, clinical professor of surgery at Stanford Health Care in Stanford, California, will serve as a co-principal investigator for the upcoming investigational device exemption (IDE) pivotal trial of Artero, FastWave Medical‘s peripheral electric intravascular lithotripsy (E-IVL) system. The news emerged today as the company announced the appointment of its principal investigators and steering committee team for the study.
Sahil Parikh, MD, director of endovascular services at Columbia University Irving Medical Center in New York, joins Chandra as a co-principal investigator. They are joined by Eric Secemsky, MD, director of vascular intervention at Beth Israel Deaconess Medical Center in Boston; Marc Bonaca, MD, a vascular medicine and cardiology doctor at the University of Colorado in Boulder; and Daniel Clair, MD, professor and chair of the department of vascular surgery at Vanderbilt University Medical Center in Nashville, who will help guide the trial’s clinical strategy.
The study will evaluate the safety and effectiveness of the Artero IVL system in treating peripheral arterial disease (PAD).
“The key question isn’t just whether a device works, but whether it makes procedures more efficient and provides physicians with a more predictable tool for treating patients with complex arterial disease,” said Chandra. “I’m excited to see how the promise of FastWave’s peripheral IVL system plays out in this study.”
